Skip to main content

Table 2 IC50 Concentrations for other human triple negative breast cancer cell lines.

From: Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer

 

BT- 549

SUM 159

HCC 1187

Gemcitabine

13.5 nM

5.27 nM

17.1 nM

UCN-01

160.8 nM

116.4 nM

230.5 nM

AZD 7762

275.2 nM

509.1 nM

307.7 nM